Company Description
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.
Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
The company’s wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste.
Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions.
The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States.
The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings.
The company was founded in 2006 and is headquartered in Marietta, Georgia.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 808 |
| CEO | Joseph Capper |
Contact Details
Address: 1775 West Oak Commons Court, NE Marietta, Georgia 30062 United States | |
| Phone | 770 651 9100 |
| Website | mimedx.com |
Stock Details
| Ticker Symbol | MDXG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001376339 |
| CUSIP Number | 602496101 |
| ISIN Number | US6024961012 |
| Employer ID | 26-2792552 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Joseph H. Capper | Chief Executive Officer and Director |
| Douglas C. Rice CPA | Chief Financial Officer |
| William F. Hulse IV | General Counsel and Chief Administrative Officer |
| Kimberly Maersk-Moller | Chief Commercial Officer |
| Dr. John Harper Ph.D. | SVice President of Research & Development and Medical Affairs and Chief Scientific Officer |
| Matthew M. Notarianni | Head of Investor Relations |
| Mark P. Graves | Senior Vice President and Chief Compliance Officer |
| Hilary Dixon | Vice President of Investor Relations and Corporate Strategic Communications |
| Eric A. Smith | Senior Vice President of Marketing and International |
| Tracy Chastain | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2026 | 8-K | Current Report |
| Apr 29, 2026 | 10-Q | Quarterly Report |
| Apr 16, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |